Skip to main content
. 2022 Jan 13;16(8):1661–1679. doi: 10.1002/1878-0261.13171

Fig. 4.

Fig. 4

Association of FAT1 signature with clinical stage of HNSCC patients. (A, B) Five‐year OS rates of FAT1‐LR and FAT1‐HR subgroups in HNSCC patients in early‐ and advanced‐stage (Stages I/II and III/IV; n = 232 and 714, respectively) were depicted using Kaplan–Meier plots. (C, D) In the same way, five‐year RFS rates of each subgroup were depicted in each clinical stage radiotherapy (n = 197 and 645, respectively). The FAT1‐HR subgroup showed significantly lower five‐year OS and RFS rates than the FAT1‐LR subgroup in HNSCC patients with advanced clinical stage (p = 7e−06 and 0.002, respectively; B, D). In early‐stage HNSCC patients, there were no significant differences in five‐year OS and RFS rates between the FAT1‐LR and FAT1‐HR subgroups. Log‐rank test was used to estimate the P value. *P < 0.05. HNSCC, head and neck squamous cell carcinoma; FAT1‐HR, FAT1‐associated high risk; FAT1‐LR, FAT1‐associated low risk; OS, overall survival; RFS, recurrence‐free survival.